Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease

Jaimin Patel, Nikhil Panicker, Valina L. Dawson, Ted M. Dawson

Research output: Contribution to journalArticlepeer-review


Parkinson’s disease is the second most prevalent neurodegenerative disease and contributes significantly to morbidity globally. Currently, no disease-modifying therapies exist to combat this disorder. Insights from the molecular and cellular pathobiology of the disease seems to indicate promising therapeutic targets. The parkin protein has been extensively studied for its role in autosomal recessive Parkinson’s disease and, more recently, its role in sporadic Parkinson’s disease. Parkin is an E3 ubiquitin ligase that plays a prominent role in mitochondrial quality control, mitochondrial-dependent cell death pathways, and other diverse functions. Understanding the numerous roles of parkin has introduced many new possibilities for therapeutic modalities in treating both autosomal recessive Parkinson’s disease and sporadic Parkinson’s disease. In this article, we review parkin biology with an emphasis on mitochondrial-related functions and propose novel, potentially disease-modifying therapeutic approaches for treating this debilitating condition.

Original languageEnglish (US)
Pages (from-to)1249-1267
Number of pages19
JournalCNS Drugs
Issue number12
StatePublished - Dec 2022

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease'. Together they form a unique fingerprint.

Cite this